Combination of a novel oncolytic immunotherapeutic agent, CAVATAK (coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and improves survival in an immune competent mouse melanoma model
Crossref DOI link: https://doi.org/10.1186/2051-1426-2-S3-P125
Published Online: 2014-11-06
Published Print: 2014-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Shafren, Darren
Quah, Min
Wong, Yvonne
Andtbacka, Robert HI
Kaufman, Howard L
Au, Gough G
Article History
First Online: 6 November 2014